Article | September 12, 2022

Enabling Long Lasting Clinical Outcomes In Coronary Stenting

Did you know that every 36 seconds, one person in the United States dies from cardiovascular disease?1 Coronary artery disease (CAD) is the most common type of cardiovascular disease and is characterized by a build-up of plaque in the arteries leading to a decreased blood supply to the heart and limbs. Early interventions such as medication or lifestyle changes can help to improve heart efficiency but do not improve the arteries already impacted by the buildup of plaque.

A primary intervention for treating CAD involves the insertion of a coronary stent into the narrowed diseased artery. Once inserted, the stent helps the artery to remain open and allow blood flow to the heart to be restored. Bare metal stents were introduced in the early nineties as an initial solution but experienced challenges in terms of in-stent restenosis and thrombosis occurrence. To help address some of these challenges, drug eluting stents (DES) were introduced in 2002 to provide a safer option and improved outcome for the patient.2

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online